Several of the discovered WEE1 inhibitors are of clinical grade and a few are in early-phase clinical development, although, currently, few trials have been specific for pancreatic cancer patients and no trials have used molecular markers of DNA damage for patient selection. The gene discussed is WEE1; the disease is pancreatic neoplasm.